

Specialty Drugs and Oncology Drugs

Authorization Process Changes Reference Sheet

Effective July 1, 2025

SPECIALTY DRUGS

| | |
|-------------------------|--|
| Requests for: | Part B specialty non-oncology drugs |
| Summary of key changes: | <ul style="list-style-type: none"> • Authorizations processed by Optum® instead of Peoples Health • Submission process redirects to MBMNow instead of staying in portal • Series and flow of questions in MBMNow differ from portal; some additional questions request patient phone number, disease state and original diagnosis date; assessment questions specific to drug being requested also apply • User experience notifies you in advance if request is for a Part D drug, which should be directed to pharmacy benefit manager • Some drugs now eligible for auto-approval, depending on indicated usage parameters |


| REQUESTS SUBMITTED PRIOR TO JULY 1, 2025 | REQUESTS SUBMITTED ON OR AFTER JULY 1, 2025 |
|--|--|
| <ul style="list-style-type: none"> • Submit all requests through UnitedHealthcare Provider Portal authorization request tool by choosing Specialty pharmacy: <div> <div>Create a new prior authorization submission</div> <div>Currently selected provider: Family Doctor Cln/laplace Edit</div> <div>Select a request category to create a new prior authorization. For some category types, such as radiology and cardiology, you will also be able to use this search to view submission status.</div> <div>Select prior authorization type for submission *</div> <div>Specialty pharmacy</div> <div>Select plan type *</div> <div>Peoples Health Plan</div> </div> | <ul style="list-style-type: none"> • Submit all requests through UnitedHealthcare Provider Portal authorization request tool by choosing Specialty pharmacy. |
| <ul style="list-style-type: none"> • Experience remains in portal. | <ul style="list-style-type: none"> • Pop-up message directs to MBMNow: <div> <div>You are being redirected.</div> <div>For the best experience, please enable popups for the UnitedHealthcare Provider Portal.</div> <div>You are now leaving the UnitedHealthcare Provider Portal and being redirected to submit your radiology prior authorization or notification request. If you are not automatically redirected in 5 seconds, please click the Continue button.</div> <div>Please note: <ul style="list-style-type: none"> • The Prior Authorization and Notification main menu will still be available behind the new window; when you're ready to return to the portal, simply close this window • For security purposes, if you've been inactive for more than 30 minutes, the portal will automatically sign you out; you will need to sign in again to access the website • If your portal session expires, you won't be automatically signed out of the UnitedHealthcare radiology request website </div> <div>Continue</div> </div> |



A UnitedHealthcare Company

**Specialty Drugs and Oncology Drugs
Authorization Process Changes Reference Sheet**
Effective July 1, 2025

SPECIALTY DRUGS

| REQUESTS SUBMITTED PRIOR TO JULY 1, 2025 | REQUESTS SUBMITTED ON OR AFTER JULY 1, 2025 |
|--|--|
| <ul style="list-style-type: none">Answer questions in portal to provide request details (diagnosis codes, place of service, dosage frequency, etc.). | <ul style="list-style-type: none">For “Authorization Type,” choose Specialty Pharmacy: Answer additional questions in MBMNow to provide request details (diagnosis codes, place of service, dosage frequency, etc.). See training presentation link in RESOURCES below for full details. |
| <ul style="list-style-type: none">Submitted request reviewed by Peoples Health.Direct questions about submitted request to Peoples Health. | <ul style="list-style-type: none">Submitted request reviewed by Optum.Direct questions about submitted request to Optum at 1-888-397-8129, Monday through Friday, from 7 a.m. to 7 p.m. CT. |

Note: Continue to submit requests for the administration of a specialty drug in the inpatient setting through the UnitedHealthcare Provider Portal request tool as an inpatient authorization request.

RESOURCES

Review [a self-paced training that shows how to submit specialty pharmacy prior authorization requests](#). Also find this training on [uhcprovider.com](#):




- Choose **Tools and resources > Education and training**
- Select **Clinical Tools**
- Choose **Specialty Guidance Program – User Guide for Authorization Request Submissions**

Find specialty Part B drugs requiring prior authorization in the [Medicare Advantage Prior Authorization List](#) (under the Medicare Advantage tab, choose the link that mentions “Peoples Health”) and in the [Medicare Part B Step Therapy Program](#) policy.

**Specialty Drugs and Oncology Drugs
Authorization Process Changes Reference Sheet**
Effective July 1, 2025

ONCOLOGY (OPTUM CANCER GUIDANCE PROGRAM) DRUGS

| | |
|--------------------------------|--|
| Requests for: | Part B cancer-supportive drugs, outpatient chemotherapy and therapeutic radiopharmaceuticals |
| Summary of key changes: | <ul style="list-style-type: none"> Singular navigation to submission link No longer requires a second login UnitedHealthcare branding, instead of Peoples Health branding |

| REQUESTS SUBMITTED PRIOR TO JULY 1, 2025 | REQUESTS SUBMITTED ON OR AFTER JULY 1, 2025 |
|---|--|
| <ul style="list-style-type: none"> Access authorization tool via MBMNow direct link (https://mbm.linkplatform.com/home) or via UnitedHealthcare Provider Portal authorization request tool by choosing Oncology:  | <ul style="list-style-type: none"> Retire any browser bookmarks to MBMNow direct link. Submit all requests through UnitedHealthcare Provider Portal authorization request tool by choosing Oncology. |
| <ul style="list-style-type: none"> Via portal, pop-up message directs to MBMNow (same link noted above):  | <ul style="list-style-type: none"> Pop-up message, similar to historical pop-up, directs to a slightly different MBMNow link:  |

**Specialty Drugs and Oncology Drugs
Authorization Process Changes Reference Sheet**
Effective July 1, 2025

ONCOLOGY (OPTUM CANCER GUIDANCE PROGRAM) DRUGS

| REQUESTS SUBMITTED PRIOR TO JULY 1, 2025 | REQUESTS SUBMITTED ON OR AFTER JULY 1, 2025 |
|---|--|
| <ul style="list-style-type: none"> MBMNow asks for login credentials: <div data-bbox="153 399 768 527"> <p>Sign in for Specialty Prior Authorizations including Cancer</p> <p>Sign In</p> </div> | <ul style="list-style-type: none"> Login credentials no longer required. |
| <ul style="list-style-type: none"> For “Authorization Type,” choose any of the following: <div data-bbox="153 605 1068 846"> <p>Authorization Type * Required</p> <p>Please select an authorization type that you would like to create. If you wish to change this selection after proceeding to the next page, you'll need to start a new request. ⓘ</p> <p>Authorization Type * <div> Cancer Supportive Drug Only Outpatient Chemotherapy Therapeutic Radiopharmaceuticals </div> </p> <p>Back Continue</p> </div> | <ul style="list-style-type: none"> For “Authorization Type,” continue to choose from options listed. |
| <ul style="list-style-type: none"> Answer additional questions in MBMNow to provide request details (diagnosis codes, place of service, dosage frequency, etc.). | <ul style="list-style-type: none"> Answer additional questions in MBMNow to provide request details (diagnosis codes, place of service, dosage frequency, etc.). All questions, functionality, drug pathways and approval processes remain the same. |

RESOURCES

Review [a self-paced training that shows how to submit oncology drug prior authorization requests](#) (shows new “access flow” described above, reiterates existing “submission flow” that continues to remain). Also find this training on uhcprovider.com:

- Choose **Coverage and payments > Prior authorization**
- Select **Oncology** tile
- Select **Oral and Injectable Chemotherapy and Related Cancer Therapies**—presentation is under the Training section

This page also includes a list of colony-stimulating factors, bone-modifying agents, antiemetic drugs and injectable chemotherapy drugs that require prior authorization when used to treat a cancer diagnosis.